A proposed US tariff plan on imported generic medicines has prompted fresh discussion about the future of India's pharmaceutical industry, with many viewing it as both a commercial challenge and an opportunity to rethink long-term strategy. Under the proposed framework announced by the US President, imported generic medicines would continue to face zero tariffs until August 1, 2028. A 100 percent tariff would then apply for one year, followed by a 200 percent tariff beginning August 1, 2029.
The proposal is intended to encourage domestic pharmaceutical manufacturing in the US. Industry observers believe the announcement underscores the importance of reducing dependence on a single export market. A CEO of a pharmaceutical company suggested that Indian manufacturers should use this period to diversify into new international markets, strengthen domestic innovation, and expand their role…
